◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › ABBV

AbbVie Inc (ABBV) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-07-02

AbbVie Inc (ABBV) operates in the Biotechnology industry and is headquartered in North Chicago, United States with about 57,000 employees. Its market capitalization is roughly $458 billion. In the fiscal year ended 2025-12-31, ABBV reported $61.2B in revenue and $4.2B in net income.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Interactive charts & full statements → Open the ABBV valuation workbench →

ABBV Revenue & Earnings History — Annual Income Statement

Income statement	TTM	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31
Total Revenue	$62.8B	$61.2B	$56.3B	$54.3B	$58.1B	$56.2B	$45.8B	$33.3B	$32.8B	$28.2B	$25.6B	$22.9B	$20.0B	$18.8B	$18.4B	$17.4B	$15.6B	$14.2B
Gross Profit	$44.4B	$43.0B	$39.4B	$33.9B	$40.6B	$38.8B	$30.4B	$25.8B	$25.0B	$21.2B	$19.8B	$18.4B	$15.5B	$14.2B	$13.9B	$12.8B	$11.3B	$10.2B
Gross Margin %	70.7%	70.2%	70.0%	62.4%	70.0%	69.0%	66.4%	77.6%	76.4%	75.0%	77.2%	80.3%	77.8%	75.6%	75.5%	73.4%	72.5%	71.5%
Operating Income (EBIT)	$17.3B	$20.1B	$9.1B	$12.8B	$18.1B	$17.9B	$11.4B	$13.0B	$6.4B	$9.5B	$9.3B	$7.5B	$3.4B	$5.7B	$5.8B	$3.6B	$4.7B	$4.9B
Operating Margin %	27.6%	32.9%	16.2%	23.5%	31.2%	31.9%	24.8%	39.0%	19.5%	33.8%	36.4%	33.0%	17.1%	30.1%	31.6%	20.8%	30.2%	34.7%
Net Income	$3.6B	$4.2B	$4.3B	$4.9B	$11.8B	$11.5B	$4.6B	$7.9B	$5.7B	$5.3B	$6.0B	$5.1B	$1.8B	$4.1B	$5.3B	$3.4B	$4.2B	$4.6B
Net Margin %	5.8%	6.9%	7.6%	8.9%	20.4%	20.5%	10.1%	23.7%	17.4%	18.8%	23.2%	22.5%	8.9%	22.0%	28.7%	19.7%	26.7%	32.6%
EBITDA	$16.9B	$17.6B	$14.9B	$17.2B	$24.2B	$23.9B	$12.3B	$12.2B	$8.3B	$10.4B	$10.1B	$8.2B	$3.6B	$6.5B	$7.0B	$4.9B	$6.0B	$5.8B
Earnings Per Share (EPS)	$10.19	$10.00	$10.12	$11.11	$13.79	$12.70	$10.51	$8.94	$7.91	$5.59	$4.82	$4.28	$3.31	$3.14	$0.98	—	—	—
Shares Outstanding (M)	1,774M	1,774M	1,773M	1,773M	1,778M	1,777M	1,673M	1,484M	1,546M	1,603M	1,631M	1,637M	1,610M	1,604M	1,577M	1,625M	1,625M	1,625M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBV Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$15.0B	$16.6B	$15.8B	$15.4B	$13.3B	$15.1B	$14.5B	$14.5B
Gross Profit	$10.8B	$12.1B	$10.5B	$11.1B	$9.3B	$10.7B	$10.2B	$10.3B
Gross Margin %	71.9%	72.6%	66.4%	71.8%	70.0%	70.9%	70.9%	70.9%
Operating Income (EBIT)	$4.7B	$5.8B	$1.9B	$4.9B	$3.7B	($1.5B)	$3.8B	$4.0B
Operating Margin %	31.6%	35.0%	12.1%	31.7%	28.0%	-9.9%	26.5%	27.6%
Net Income	$699M	$1.8B	$186M	$938M	$1.3B	($22M)	$1.6B	$1.4B
Net Margin %	4.7%	10.9%	1.2%	6.1%	9.6%	-0.1%	10.8%	9.5%
EBITDA	$3.7B	$5.4B	$3.5B	$4.3B	$4.4B	$535M	$4.9B	$5.0B
Earnings Per Share (EPS)	$2.65	$2.71	$1.86	$2.97	$2.46	$2.16	$3.00	$2.65
Shares Outstanding (M)	1,774M	1,774M	1,772M	1,772M	1,772M	1,773M	1,772M	1,771M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBV Free Cash Flow History

Cash flow	TTM	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31
Cash from Operations (CFO)	$21.2B	$19.0B	$18.8B	$22.8B	$24.9B	$22.8B	$17.6B	$13.3B	$13.4B	$10.0B	$7.0B	$7.5B	$3.5B	$6.3B	$6.3B	$6.2B	$5.0B	$5.4B
Capital Expenditures (CapEx)	$1.4B	$1.2B	$974M	$777M	$695M	$787M	$798M	$552M	$638M	$529M	$479M	$532M	$612M	$491M	$333M	$356M	$448M	$313M
Free Cash Flow (FCF)	$19.9B	$17.8B	$17.8B	$22.1B	$24.2B	$22.0B	$16.8B	$12.8B	$12.8B	$9.4B	$6.6B	$7.0B	$2.9B	$5.8B	$6.0B	$5.9B	$4.5B	$5.1B
FCF Margin %	31.6%	29.1%	31.6%	40.6%	41.8%	39.1%	36.7%	38.4%	39.1%	33.4%	25.6%	30.6%	14.7%	30.7%	32.7%	33.8%	29.0%	35.6%
Dividends Paid	$11.8B	$11.7B	$11.0B	$10.5B	$10.0B	$9.3B	$7.7B	$6.4B	$5.6B	$4.1B	$3.7B	$3.3B	$2.7B	$2.6B	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBV Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$3.8B	$5.2B	$7.0B	$5.2B	$1.6B	$7.0B	$5.4B	$2.3B
Capital Expenditures (CapEx)	$265M	$329M	$504M	$269M	$235M	$291M	$249M	$241M
Free Cash Flow (FCF)	$3.6B	$4.9B	$6.5B	$4.9B	$1.4B	$6.8B	$5.2B	$2.0B
FCF Margin %	23.8%	29.4%	41.3%	31.7%	10.5%	44.7%	35.9%	14.0%
Dividends Paid	$3.1B	$2.9B	$2.9B	$2.9B	$2.9B	$2.8B	$2.8B	$2.8B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBV Balance Sheet History

Balance sheet	MRQ	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$136.5B	$134.0B	$135.2B	$134.7B	$138.8B	$146.5B	$150.6B	$89.1B	$59.4B	$70.8B	$66.1B	$53.0B	$27.5B	$29.2B	$27.0B	$19.5B	$21.1B
Cash & Cash Equivalents	$9.4B	$5.2B	$5.5B	$12.8B	$9.2B	$9.7B	$8.4B	$39.9B	$7.3B	$9.3B	$5.1B	$8.4B	$8.3B	$9.6B	$5.9B	$27M	$10M
Total Liabilities	$143.1B	$137.2B	$131.8B	$124.3B	$121.5B	$131.1B	$137.5B	$97.3B	$67.8B	$65.7B	$61.5B	$49.1B	$25.8B	$24.7B	$23.6B	$7.6B	$5.4B
Total Debt (Short + Long-Term)	$72.9B	$67.7B	$67.1B	$59.4B	$63.4B	$76.9B	$86.2B	$66.7B	$40.3B	$37.4B	$36.8B	$31.7B	$15.0B	$14.7B	$15.7B	$53M	$0M
Total Shareholders' Equity	($6.6B)	($3.2B)	$3.4B	$10.4B	$17.3B	$15.4B	$13.1B	($8.2B)	($8.4B)	$5.1B	$4.6B	$3.9B	$1.7B	$4.5B	$3.4B	$11.9B	$15.7B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABBV viewer.

Other Companies in Biotechnology

AMGN · Amgen — $203 billion
GILD · Gilead Sciences — $161 billion
VRTX · Vertex Pharmaceuticals — $121 billion
REGN · Regeneron Pharmaceuticals — $69 billion
BIIB · Biogen — $30 billion
ROIV · Roivant Sciences Ltd. — $26 billion
INSM · Insmed Incorporated — $26 billion
INCY · Incyte — $24 billion

← ABAT All stocks ABCB →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.